In imatinib-treated CML cells, inhibition of BCR-ABL tyrosine-kinase activity restores NEAT1 expression and causes apoptosis via the BCR-ABL/c-MYC/NEAT1/SFPQ axis [65]. The gene discussed is MYC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.